Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

New Lab Test Helps Predict Kidney Damage
Acute kidney injury (AKI) is a frequent complication in patients in intensive care. A new laboratory test called urine neutrophil gelatinase associated lipocalin (NGAL) helps predict if patients will develop acute kidney injury, reports an upcoming study in the Journal of the American Society of Nephrology (JASN). "As a stand-alone marker, urine NGAL performed moderately well in predicting ongoing and subsequent AKI," comments T. Alp Ikizler, MD (Vanderbilt University).
generic viagra online
Meckel's Diverticulum Masked By Intermittent Recurrent Subocclusive Episodes
Meckel"s diverticulum (MD) is the most frequent congenital abnormality of the small bowel and it is often difficult to diagnose. It is usually asymptomatic but approximately 4% are symptomatic with complications such as bleeding, intestinal obstruction, and inflammation. Daniela Codrich et al presents a case of Meckel"s diverticulum masked by a long period of intermittent recurrent subocclusive episodes. Their findings were published on June 14, 2009 in the World Journal of Gastroenterology. Drugshop to buy zoloft online and other pills.
News of the day
UNICEF Launches Kit To Help Young Children Caught In Emergencies
A new kit to help meet the developmental needs of young children affected by emergencies was launched in Geneva by UNICEF Executive Director, Ann M. Veneman.
Sexual Health

New Data Show Cost Savings Achieved By Treating Mild And Moderate Alzheimer's Patients With Aricept(R)

Researchers attending the annual meeting of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR), heard today that prescribing Aricept® (donepezil hydrochloride) as soon as patients are diagnosed with either mild or moderate Alzheimer"s disease saves the NHS money. The findings contradict the recommendation by NICE that these medicines are not cost effective in the early stages of the disease, a decision that has been the subject of much recent debate. The study shows that direct savings to the NHS over a ten year period average over ÷£4,000 per patient for those starting treatment in the mild stages of the disease. Total savings to society rise to ÷£7,100 per patient when the cost of care giver"s time is included. The average direct saving to the NHS over the same period for patients across the mild and moderate stages of the disease was estimated to be ÷£2,300 per patient, and for society ÷£4,800 when care giver"s time is taken into account. The study, sponsored by Eisai, uses more accurate calculations and more up-to-date costs of Alzheimer"s disease treatment than were used in the analyses undertaken by NICE, and the authors conclude that their findings indicate the decision taken by NICE to restrict treatment to patients with moderate Alzheimer"s disease was highly questionable. ISPOR


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009